• Clinical and Pharmacoeconomic Aspects of Omalizumab Clinical and Pharmacoeconomic Aspects of Omalizumab For patients with severe persistent allergic asthma, treatment with omalizumab may provide a cost-effective alternative.
  • Portopulmonary Hypertension Portopulmonary Hypertension Pulmonary hypertension in patients with liver disease or portal hypertension may be due to multiple mechanisms.
  • New AMA Head on Membership, the ACA, and Medicine's Future New AMA Head on Membership, the ACA, and Medicine's Future   Dr. James Madara, of the American Medical Association, gives a candid interview on the nation's largest physician organization and whether it has any regrets about supporting the Affordable Care Act.
  • New Therapies for Pneumonia New Therapies for Pneumonia New antibiotic shortages combined with the increasing number of antibioticresistant bacteria creates a threat for the global population and a critical challenge for healthcare institutions.
 
 

Pulmonary Medicine News
 – From Medscape Medical News, Reuters and more

  • Medicare Spotlights Hospitals With Especially Costly Patients Medicare Spotlights Hospitals With Especially Costly Patients The government has identified hundreds of hospitals whose Medicare patients are incurring especially high bills, a first step toward using bonuses and penalties to encourage more efficient care.
  • Cystic Fibrosis Combo Therapy Shows Promise Cystic Fibrosis Combo Therapy Shows Promise Vertex Pharmaceuticals Inc's new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease (VX-809), led to significant improvement in lung function in a mid-stage study.
 

Pulmonary Medicine Perspectives

Physician Compensation Report 2012
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC. This website also contains material copyrighted by 3rd parties.